Mechanism of action, potency and efficacy: considerations for cell therapies.

Autor: Simon CG Jr; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA. carl.simon@nist.gov., Bozenhardt EH; United Therapeutics Corporation, Regenerative Medicine Operations, Research Triangle Park, NC, USA., Celluzzi CM; Association for the Advancement of Blood and Biotherapies (AABB), Bethesda, MD, USA., Dobnik D; Niba Labs, Ljubljana, Slovenia.; National Institute of Biology, Ljubljana, Slovenia., Grant ML; Department of Pediatrics, Children's Healthcare of Atlanta, Marcus Center for Cellular and Gene Therapies, Correlative Studies Laboratory, Emory University School of Medicine, Atlanta, GA, USA., Lakshmipathy U; Pharma Services, Science and Technology, Thermo Fisher Scientific, San Diego, CA, USA., Nebel T; Medical Education, Sports Medicine and Orthobiologics, Medical Sales Institute, San Diego, CA, USA., Peltier L; Cellular Therapy Lab, Research Institute of McGill University Health Center, Montreal, QC, Canada., Ratcliffe A; Synthasome, Inc, San Diego, CA, USA., Sherley JL; Asymmetrex, LLC, Boston, MA, USA., Stacey GN; International Stem Cell Banking Initiative, Barley, Herts, UK.; National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cells and Regenerative Medicine, Chinese Academy of Sciences, Beijing, China., Taghizadeh RR; Kendall Innovations, Cambridge, MA, USA., Tan EHP; Cell and Gene Therapy Facility, Health Sciences Authority, Singapore, Singapore., Vessillier S; Science, Research and Innovation Group, Biotherapeutics and Advanced Therapies Division, Medicines and Healthcare Products Regulatory Agency, South Mimms, Hertfordshire, UK.

Publikováno v: Journal of translational medicine [J Transl Med] 2024 May 02; Vol. 22 (1), pp. 416. Date of Electronic Publication: 2024 May 02.